The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 41, Issue 5, 2001, Pages 528-535

  Cass, Lindsey M ^a   Moore, Katy H P ^a   Dallow, Nigel S ^a   Jones, Anne E ^a   Sisson, Jonathan R ^b   Prince, William T ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 7 FLUORO 1,2,3,4 TETRAHYDRO 3 OXO 1 QUINOXALINECARBOXYLIC ACID ISOPROPYL ESTER; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; FAT INTAKE; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DIETARY FATS; FOOD-DRUG INTERACTIONS; GASTROINTESTINAL DISEASES; HALF-LIFE; HEADACHE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; QUINOXALINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035038230     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010401     Document Type: Article

References (27)

1. GW420867X, a new non-nucleoside reverse transcriptase inhibitor (NNRTI): Initial phase I evaluation
2. GW420867X: A novel quinoxaline-class NNRTI of HIV-1 with improved antiretroviral properties in the presence of human serum and its components
3. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors
4. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication
5. NNRTI GW420867X: Comparative evaluation of the in vitro resistance profile
6. GW420867X, a new non-nucleoside reverse transcriptase inhibitor, single and repeat dose pharmacokinetics (PK)
7. Adherence: A necessity for successful HIV combination therapy
8. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance
9. The use of non-parametric methods in the statistical analysis of the two periods change-over design
10. Logarithmic transformation in bioequivalence: Application with two formulations of perphenazine
11. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS
12. Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection
13. Effects of food or antacid on the bioavailability of nevirapine 200mg in 24 healthy volunteers
14. Single-dose pharmacokinetic (PK) studies with delavirdine (DLV) mesylate: Dose proportionality and effects of food and antacid
15. Effect of food on the steady-state (ss) pharmacokinetics of delavirdine mesylate in HIV+ patients
16. Pharmacokinetics (PK) and safety of single escalating doses of MKC-442 in HIV-infected volunteers
17. The use of pharmacoscintigraphy to elucidate food effects observed with a novel protease inhibitor (saquinavir)
18. Pharmacokinetics of the HIV-protease inhibitor, Ro 318959, after single and multiple oral doses in healthy volunteers
19. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation
20. Single-dose pharmacokinetics of indinavir and the effect of food
21. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
22. Hope and caution: Report from the 6th International Conference on AIDS
23. Combination therapy from a clinician's perspective
24. Antiviral therapy with zidovudine (AZT): Evaluation of the compliance in a cohort of HIV+ patients
25. Cost-effectiveness of once-daily oral antimicrobial therapy